Compugen First Quarter 2011 Webcast and Conference Call Scheduled for Wednesday, May 11, 2011 at 10:00 AM EDT
03 May 2011 - 11:00PM
Business Wire
Compugen Ltd. (NASDAQ: CGEN) today announced that the Company
will host a live webcast and conference call at 10:00 AM EDT on
Wednesday, May 11, 2011 to review first quarter 2011 results and to
present an updated slide presentation of the company’s current
status and outlook. The quarterly results will be released, and the
slide presentation posted on the company’s website (www.cgen.com),
prior to the conference call.
To access the live webcast and presentation slides please go to
Compugen’s website, located at www.cgen.com. The audio portion will
also be available via conference call, which can be accessed by
dialing 1-888-407-2553 from the US, or +972-3-918-0610
internationally.
A replay of the conference call will be available approximately
two hours after the completion of the live conference call. To
access the replay, please dial 1-888-295-2634 from the US or
+972-3-925-5928 internationally. The replay will be available
through May 14, 2011.
About Compugen
Compugen is a leading drug and diagnostic discovery company
providing novel product candidates addressing important unmet
therapeutic and diagnostic needs to pharmaceutical, biotech and
diagnostic companies under milestone and royalty bearing or other
revenue sharing agreements. Unlike traditional high throughput
trial and error experimental based discovery, Compugen's discovery
efforts consist of in silico (by computer) hypothesis-driven
product candidate prediction and selection followed by in vitro and
in vivo experimental validation. Compugen's unique in silico
prediction and selection capabilities are based on a broad and
continuously growing infrastructure of proprietary scientific
understandings and predictive platforms, algorithms, machine
learning systems and other computational biology tools. Industry
collaborations may be entered into before product candidate
discovery is undertaken pursuant to "discovery on demand" type
arrangements, or with respect to existing product candidates, can
be initiated prior to, or at the proof of concept stage, or after
selected preclinical activities have been undertaken by Compugen.
In 2002, Compugen established an affiliate, Evogene Ltd.
(www.evogene.com) (TASE:EVGN.TA), to utilize certain of the
Company's in silico predictive discovery capabilities in
agricultural biotechnology. For additional information, please
visit Compugen's corporate website at www.cgen.com.
This press release may contain "forward-looking statements"
within the meaning of the Private Securities Litigation Reform Act
of 1995. These statements include words such as "may," "expects,"
"anticipates," "believes," and "intends," and describe opinions
about future events. These forward-looking statements involve known
and unknown risks and uncertainties that may cause the actual
results, performance or achievements of Compugen to be materially
different from any future results, performance or achievements
expressed or implied by such forward-looking statements. Some of
these risks are: changes in relationships with collaborators; the
impact of competitive products and technological changes; risks
relating to the development of new products; and the ability to
implement technological improvements. These and other factors are
identified and more fully explained under the heading "Risk
Factors" in Compugen's annual reports filed with the Securities and
Exchange Commission.
Compugen (NASDAQ:CGEN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Compugen (NASDAQ:CGEN)
Historical Stock Chart
From Jul 2023 to Jul 2024